Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients

Scoggins, Charles R.; Martin, Robert C.G.; Ross, Merrick I.; Edwards, Michael J.; Reintgen, Douglas S.; Urist, Marshall M.; Gershenwald, Jeffrey E.; Sussman, Jeffrey J.; Noyes, R. Dirk; Goydos, James S.; Beitsch, Peter D.; Ariyan, Stephan; Stromberg, Arnold J.; Hagendoorn, Lee; McMasters, Kelly M.

doi:10.1245/s10434-009-0858-x

Cited by 98 publications

(112 citation statements)

References 33 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…11 Amongst other investigators, we have found comparable results in earlier studies: in line with other studies using this definition and an earlier report from our hospital the false-negative rate in the current study is 11%. 3,12 Remarkably, however, the false-negative rate recently dropped to 2% in our center. Recently data from the Sunbelt Melanoma Trial by Scoggins et al show no OS difference between patients with a false-negative SLN and patients with a true-positive SLN result.…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 59%

“…Recently data from the Sunbelt Melanoma Trial by Scoggins et al show no OS difference between patients with a false-negative SLN and patients with a true-positive SLN result. 12 However, the authors discuss that their finding is also somewhat at odds with the MSLT, which showed that the survival of patients who developed clinically detected nodal metastases in de wide local excision-only group was worse than those who had nodal metastases detected by the SLNB.…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 95%

See 1 more Smart Citation

Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma

Vries¹,

Speijers²,

Bastiaannet³

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

, et al.. Long-term followup reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma. EJSO -European Journal of Surgical Oncology, WB Saunders, 2011, 37 (8) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 124 Patients (29%) relapsed during follow-up; 55 in the node-positive group who underwent CLND (55/119;46%) and 69 in the node-negative group (69/310;22%;p<0.001). In the node-negative group 17 patients developed recurrence in the regional node field; false-negative rate 11%.On multivariate analysis strongest prognostic factors for disease free survival (DFS) were primary melanoma ulceration and SLN positivity (Hazard Ratio (HR) of 2.2 and 2.3; p<0.001). For disease specific survival (DSS) the same was found to be true with a HR of 2.1 for ulceration and 2.0 for SLN positivity (p=0.001 and p=0.002 respectively). 10-Year DFS was 71% for node-negative patients compared with 48% for node-positive patients (p<0.001). 10-Year DSS was 77% for node-negative patients compared to 60% for node-positive patients (p<0.001).Conclusions: This study shows a remarkably high percentage of tumor-positive SLN. The long-term follow-up data confirm that tumor-positive SLN patients have a worse DFS and DSS than tumornegative SLN patients. Ulceration and SLN status proved to be the strongest prognostic factors for long-term DFS and DSS.

show abstract

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 59%

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 95%

Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma

Vries¹,

Speijers²,

Bastiaannet³

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…Neuschmelting, H.L., J.G., and M.F.K. have no conflicts of interest to the local nodal basin at the time of SLN excision (in-transit metastases) (6,(8)(9)(10)(11).…”

Section: Methodsmentioning

confidence: 99%

Lymph Node Micrometastases and In-Transit Metastases from Melanoma: In Vivo Detection with Multispectral Optoacoustic Imaging in a Mouse Model

Neuschmelting¹,

Lockau

Ntziachristos

et al. 2016

Radiology

View full text Add to dashboard Cite

“…There are numerous reports of the natural history after a positive sentinel node biopsy. 7,8,35,36,40,45,[50][51][52][53][54] In their meta-analysis, Mehrany and coworkers report a 66% disease-free survival rate after a positive sentinel lymph node biopsy. Over a median follow-up period of 10.5 months, the odds of recurrence were 19-fold greater in patients with a positive biopsy than in patients with a negative sentinel node biopsy (odds ratio 18.9, P ϭ 0.005).…”

Section: Positive Sentinel Lymph Node Biopsymentioning

confidence: 99%

The Surgical Management of Primary and Metastatic Merkel Cell Carcinoma

Gonzalez

Padhya

Cherpelis

et al. 2010

Current Problems in Cancer

View full text Add to dashboard Cite

Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients

Cited by 98 publications

References 33 publications

Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma

Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma

Lymph Node Micrometastases and In-Transit Metastases from Melanoma: In Vivo Detection with Multispectral Optoacoustic Imaging in a Mouse Model

The Surgical Management of Primary and Metastatic Merkel Cell Carcinoma

Contact Info

Product

Resources

About